Travere Therapeutics (TVTX) Change in Accured Expenses (2011 - 2026)

Travere Therapeutics (TVTX) has 16 years of Change in Accured Expenses data on file, last reported at $1.9 million in Q1 2026.

• Quarterly Change in Accured Expenses rose 173.62% year-over-year to $1.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$8.5 million (up 77.9% YoY) and the FY2025 annual result came in at -$9.7 million, up 44.77% from the prior year.
• Change in Accured Expenses grew to $1.9 million in Q1 2026, from -$21.2 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $24.3 million in Q4 2022 to a low of -$44.0 million in Q3 2024.
• A 5-year average of $1.3 million and a median of $709000.0 in 2025 frame the typical range for Change in Accured Expenses.
• Annual changes were most pronounced in 2023 — Change in Accured Expenses surged 184562.5% — and 2024, when it plunged 397.51%.
• Tracing TVTX's Change in Accured Expenses over 5 years: stood at $24.3 million in 2022, then declined by 28.83% to $17.3 million in 2023, then increased by 22.76% to $21.2 million in 2024, then sank by 199.86% to -$21.2 million in 2025, then surged by 109.15% to $1.9 million in 2026.
• The last three Change in Accured Expenses figures came in at $1.9 million (Q1 2026), -$21.2 million (Q4 2025), and $19.7 million (Q3 2025), per Business Quant data.